» Articles » PMID: 39871287

HMOX1 As a Potential Drug Target for Upper and Lower Airway Diseases: Insights from Multi-omics Analysis

Overview
Journal Respir Res
Date 2025 Jan 28
PMID 39871287
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oxidative stress is key in inflammatory airway diseases. Heme oxygenase 1 (HMOX1) regulates oxidative stress, but its role in airway diseases needs exploration.

Methods: Differentially expressed genes (DEGs) between healthy nasal mucosa and chronic rhinosinusitis with nasal polyps (CRSwNP) were identified from Gene Expression Omnibus (GEO). Candidate genes were further screened using Gene Set Enrichment Analysis (GSEA) and Random Forest (RF) algorithms. Causal inference between candidate genes and upper and lower airway diseases (CRSwNP, allergic rhinitis (AR), and asthma (AS)) was conducted using bidirectional two-sample Mendelian randomization (TwoSampleMR) analysis. Single-cell RNA sequencing (scRNA-seq) data were used to determine the cellular localization and intercellular interactions of candidate genes. Molecular docking was used to identify potential therapeutic agents.

Results: HMOX1 expression was significantly elevated in CRSwNP. TwoSampleMR analysis indicated a negative causal relationship between HMOX1 exposure and the occurrence of upper and lower airway diseases (CRSwNP [(odds ratio (OR)/95% confidence interval (CI): 0.945/(0.893-0.999), P = 0.044], AR [OR/95% CI: 0.997/(0.994-0.999), P = 0.007], and AS [OR/95% CI: 0.935/(0.895-0.977), P = 0.003]). scRNA-seq data revealed HMOX1 localization in M2 macrophages. Molecular docking identified 15 antioxidants, including Acetylcysteine and Quercetin, that can upregulate HMOX1 expression.

Conclusion: HMOX1 may have a protective role in the pathogenesis of upper and lower airway diseases (CRSwNP, AR, and AS) by modulating oxidative stress. Antioxidants that increase HMOX1 expression could offer new therapeutic avenues for these diseases.

Clinical Trial: Not applicable.

References
1.
Bui T, Fan Y, Piao C, Nguyen T, Shin D, Jung S . Piper Nigrum extract improves OVA-induced nasal epithelial barrier dysfunction via activating Nrf2/HO-1 signaling. Cell Immunol. 2020; 351:104035. DOI: 10.1016/j.cellimm.2019.104035. View

2.
Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

3.
Kumar K, Lodha R, Jat K, Jain V, Kabra S . Prevalence of Metabolic Abnormalities and their Association with Asthma Symptom Control in Children. Indian J Pediatr. 2023; 91(5):434-440. DOI: 10.1007/s12098-023-04716-4. View

4.
Licari A, Castagnoli R, Denicolo C, Rossini L, Marseglia A, Marseglia G . The Nose and the Lung: United Airway Disease?. Front Pediatr. 2017; 5:44. PMC: 5334318. DOI: 10.3389/fped.2017.00044. View

5.
Dang X, He B, Ning Q, Liu Y, Guo J, Niu G . Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways. Respir Res. 2020; 21(1):95. PMC: 7178609. DOI: 10.1186/s12931-020-01358-4. View